Original paper

Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease

Volume: 150, Pages: 105369 - 105369
Published: Jul 1, 2020
Abstract
Inflammatory bowel disease (IBD) is commonly treated with adalimumab. The main objective of the study was to develop a population pharmacokinetic model of adalimumab in IBD patients evaluating the potential biomarkers of disease activity and other factors and its implications in adalimumab dosing. A prospective observational study was performed in adult patients diagnosed with Crohn's disease and ulcerative colitis treated with adalimumab and...
Paper Details
Title
Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease
Published Date
Jul 1, 2020
Volume
150
Pages
105369 - 105369
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.